{Reference Type}: Journal Article
{Title}: Contribution of Cyclin-dependent Kinase Inhibitor 1B Genotypes to Childhood Leukemia Risk.
{Author}: Pei JS;Chang WS;Hsu PC;Chen CC;Yang YC;Hsu SW;Hsu YN;Wang YC;Wang CH;Tsai CW;Bau DT;
{Journal}: In Vivo
{Volume}: 36
{Issue}: 4
{Year}: Jul-Aug 2022
{Factor}: 2.406
{DOI}: 10.21873/invivo.12874
{Abstract}: <B>OBJECTIVE: </B>Although genetic differences in cell-cycle control genes have been associated with cancer risk, to our knowledge, no report has specifically examined the role of gene variants in childhood acute lymphoblastic leukemia (ALL). Cyclin-dependent kinase inhibitor 1B (CDKN1B; also known as p27/KIP1) is a cell-cycle regulating gene. This study aimed at investigating the association between CDKN1B genotypes and childhood ALL risk.<BR><B>METHODS: </B>In 266 childhood ALL cases and 266 healthy controls, the CDKN1B rs34330 and 2066827 polymorphisms were genotyped, and the association of CDKN1B genotypes with childhood ALL risk were analyzed.<BR><B>RESULTS: </B>The genotypes of CDKN1B rs34330 and 2066827 were similarly distributed between the control and case groups (p for trend=0.8718 and 0.4030, respectively). The allelic frequency also exhibited no statistical difference (p=1.0000 and 0.6666, respectively). There was no significant interaction between CDKN1B genotypes and age or sex.<BR><B>CONCLUSIONS: </B>CDKN1B genotypes were not found to be minor contributors to childhood ALL susceptibility in Taiwan.